

# Sandra Coral

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3021735/sandra-coral-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

41  
papers

2,093  
citations

25  
h-index

45  
g-index

48  
ext. papers

2,281  
ext. citations

7.5  
avg, IF

3.99  
L-index

#	Paper	IF	Citations
41	Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival. <i>Cancers</i> , <b>2020</b> , 12,	6.6	14
40	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 7351-7362	12.9	33
39	Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1443	5.6	11
38	"Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013. <i>Cancer Immunology, Immunotherapy</i> , <b>2015</b> , 64, 131-34	7.4	7
37	Epigenetics meets immune checkpoints. <i>Seminars in Oncology</i> , <b>2015</b> , 42, 506-13	5.5	28
36	Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. <i>Onc Immunology</i> , <b>2015</b> , 4, e1019978	7.2	46
35	Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4040-7	12.9	75
34	Epigenetic drugs as immunomodulators for combination therapies in solid tumors. <i>Pharmacology &amp; Therapeutics</i> , <b>2014</b> , 142, 339-50	13.9	74
33	Epigenetic markers of prognosis in melanoma. <i>Methods in Molecular Biology</i> , <b>2014</b> , 1102, 481-99	1.4	5
32	Immunomodulatory activity of SGI-110, a 5-aza-2'deoxyctidine-containing demethylating dinucleotide. <i>Cancer Immunology, Immunotherapy</i> , <b>2013</b> , 62, 605-14	7.4	49
31	Epigenetics of melanoma: implications for immune-based therapies. <i>Immunotherapy</i> , <b>2013</b> , 5, 1103-16	3.8	13
30	Whole genome methylation profiles as independent markers of survival in stage IIIc melanoma patients. <i>Journal of Translational Medicine</i> , <b>2012</b> , 10, 185	8.5	35
29	Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications. <i>British Journal of Cancer</i> , <b>2012</b> , 107, 1116-24	8.7	17
28	The biology of cancer testis antigens: putative function, regulation and therapeutic potential. <i>Molecular Oncology</i> , <b>2011</b> , 5, 164-82	7.9	222
27	Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. <i>Journal of Translational Medicine</i> , <b>2011</b> , 9, 78	8.5	45
26	Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. <i>Cardiovascular Research</i> , <b>2010</b> , 86, 12-9	9.9	130
25	Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. <i>Journal of Translational Medicine</i> , <b>2010</b> , 8, 56	8.5	79

24	Cancer testis antigens and melanoma stem cells: new promises for therapeutic intervention. <i>Cancer Immunology, Immunotherapy</i> , <b>2010</b> , 59, 487-8	7.4	4
23	Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. <i>Journal of Cellular Physiology</i> , <b>2010</b> , 223, 352-8	7	18
22	Epigenetically regulated tumor-associated antigens in melanoma. <i>Expert Review of Dermatology</i> , <b>2009</b> , 4, 145-154		1
21	Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. <i>Journal of Cellular Physiology</i> , <b>2007</b> , 212, 330-44	7	107
20	Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2-Deoxycytidine in cutaneous melanoma: immunotherapeutic implications. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 3333-8	12.9	101
19	5-AZA-2-Deoxycytidine in cancer immunotherapy: a mouse to man story. <i>Cancer Research</i> , <b>2007</b> , 67, 2900-1; author reply 2901-2	10.1	21
18	Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. <i>Journal of Cellular Physiology</i> , <b>2006</b> , 207, 58-66	7	46
17	Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. <i>Seminars in Oncology</i> , <b>2005</b> , 32, 473-8	5.5	42
16	Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2-Deoxycytidine. <i>Cancer Research</i> , <b>2004</b> , 64, 9167-71	10.1	172
15	Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 748-54	5.6	55
14	Methylation-regulated expression of HLA class I antigens in melanoma. <i>International Journal of Cancer</i> , <b>2003</b> , 105, 430-1; author reply 432-3	7.5	34
13	Epigenetic targets for immune intervention in human malignancies. <i>Oncogene</i> , <b>2003</b> , 22, 6484-8	9.2	62
12	Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells. <i>Journal of Cellular Physiology</i> , <b>2002</b> , 190, 200-6	7	5
11	Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. <i>Journal of Immunotherapy</i> , <b>2002</b> , 25, 16-26	5	104
10	5-aza-2-Deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 2690-5	12.9	105
9	Unbalanced expression of HLA-A and -B antigens: a specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN-gamma. <i>International Journal of Cancer</i> , <b>2001</b> , 91, 500-7	7.5	10
8	Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. <i>Journal of Cellular Physiology</i> , <b>2001</b> , 188, 1-7	7	148
7	Unbalanced expression of HLA-A and -B antigens: A specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN- $\gamma$ . <i>International Journal of Cancer</i> , <b>2001</b> , 91, 500		1

6	Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement. <i>Journal of Cellular Physiology</i> , <b>2000</b> , 185, 317-23	7	25
5	In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells. <i>Cancer Immunology, Immunotherapy</i> , <b>1999</b> , 48, 132-8	7.4	8
4	Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2-Deoxycytidine (5-AZA-CdR). <i>Journal of Immunotherapy</i> , <b>1999</b> , 22, 16-24	5	114
3	Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity. <i>International Journal of Cancer</i> , <b>1995</b> , 61, 548-56	7.5	32
2	Epigenetically-Regulated Therapeutic Tumor-Associated Antigens143-160		
1	Epigenetic Mechanisms in Cancer Formation and Progression253-298		2